IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®

NAActive, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Inflammatory Bowel Diseases

Interventions

OTHER

Biocollection

Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.

Trial Locations (1)

Saint Antoine Hospital Service de Gastroentérologie et Nutrition, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER